AIM: To propose an alternative model of hepatic encephalopathy (HE) in mice, resembling the human features of the disease. METHODS: Mice received two consecutive intraperitoneal injections of thioacetamide (TAA) at low dosage (300 mg/kg). Liver injury was assessed by serum transaminase levels (ALT) and liver histology (hematoxylin and eosin). Neutrophil infiltration was estimated by confocal liver intravital microscopy. Coagulopathy was evaluated using prolonged prothrombin and partial thromboplastin time. Hemodynamic parameters were measured through tail cuff. Ammonia levels were quantified in serum and brain samples. Electroencephalography (EEG) and psychomotor activity score were performed to show brain function. Brain edema was evaluated using magnetic resonance imaging. RESULTS: Mice submitted to the TAA regime developed massive liver injury, as shown by elevation of serum ALT levels and a high degree of liver necrosis. An intense hepatic neutrophil accumulation occurred in response to TAA-induced liver injury. This led to mice mortality and weight loss, which was associated with severe coagulopathy. Furthermore, TAA-treated mice presented with increased serum and cerebral levels of ammonia, in parallel with alterations in EEG spectrum and discrete brain edema, as shown by magnetic resonance imaging. In agreement with this, neuropsychomotor abnormalities ensued 36 h after TAA, fulfilling several HE features observed in humans. In this context of liver injury and neurological dysfunction, we observed lung inflammation and alterations in blood pressure and heart rate that were indicative of multiple organ dysfunction syndrome. CONCLUSION: In summary, we describe a new murine model of hepatic encephalopathy comprising multiple features of the disease in humans, which may provide new insights for treatment.
AIM: To propose an alternative model of hepatic encephalopathy (HE) in mice, resembling the human features of the disease. METHODS:Mice received two consecutive intraperitoneal injections of thioacetamide (TAA) at low dosage (300 mg/kg). Liver injury was assessed by serum transaminase levels (ALT) and liver histology (hematoxylin and eosin). Neutrophil infiltration was estimated by confocal liver intravital microscopy. Coagulopathy was evaluated using prolonged prothrombin and partial thromboplastin time. Hemodynamic parameters were measured through tail cuff. Ammonia levels were quantified in serum and brain samples. Electroencephalography (EEG) and psychomotor activity score were performed to show brain function. Brain edema was evaluated using magnetic resonance imaging. RESULTS:Mice submitted to the TAA regime developed massive liver injury, as shown by elevation of serum ALT levels and a high degree of liver necrosis. An intense hepatic neutrophil accumulation occurred in response to TAA-induced liver injury. This led to mice mortality and weight loss, which was associated with severe coagulopathy. Furthermore, TAA-treated mice presented with increased serum and cerebral levels of ammonia, in parallel with alterations in EEG spectrum and discrete brain edema, as shown by magnetic resonance imaging. In agreement with this, neuropsychomotor abnormalities ensued 36 h after TAA, fulfilling several HE features observed in humans. In this context of liver injury and neurological dysfunction, we observed lung inflammation and alterations in blood pressure and heart rate that were indicative of multiple organ dysfunction syndrome. CONCLUSION: In summary, we describe a new murine model of hepatic encephalopathy comprising multiple features of the disease in humans, which may provide new insights for treatment.
Authors: Braedon McDonald; Keir Pittman; Gustavo B Menezes; Simon A Hirota; Ingrid Slaba; Christopher C M Waterhouse; Paul L Beck; Daniel A Muruve; Paul Kubes Journal: Science Date: 2010-10-15 Impact factor: 47.728
Authors: Y Avraham; Nc Grigoriadis; T Poutahidis; L Vorobiev; I Magen; Y Ilan; R Mechoulam; Em Berry Journal: Br J Pharmacol Date: 2011-04 Impact factor: 8.739
Authors: Fernando A Bozza; Philippe Garteiser; Marcus F Oliveira; Sabrina Doblas; Rebecca Cranford; Debra Saunders; Inna Jones; Rheal A Towner; Hugo C Castro-Faria-Neto Journal: J Cereb Blood Flow Metab Date: 2009-10-21 Impact factor: 6.200
Authors: Heather Hajovsky; Gang Hu; Yakov Koen; Diganta Sarma; Wenqi Cui; David S Moore; Jeff L Staudinger; Robert P Hanzlik Journal: Chem Res Toxicol Date: 2012-08-17 Impact factor: 3.739
Authors: M Farjam; P Dehdab; F Abbassnia; D Mehrabani; N Tanideh; S Pakbaz; M H Imanieh Journal: Iran Red Crescent Med J Date: 2012-03-01 Impact factor: 0.611
Authors: Stephanie Grant; Matthew McMillin; Gabriel Frampton; Anca D Petrescu; Elaina Williams; Victoria Jaeger; Jessica Kain; Sharon DeMorrow Journal: Gene Expr Date: 2018-06-12
Authors: Erika Guimarães; Rodrigo Machado; Matheus de Castro Fonseca; Andressa França; Clarissa Carvalho; Ana Cândida Araújo E Silva; Brígida Almeida; Puebla Cassini; Bárbara Hissa; Luciana Drumond; Carlos Gonçalves; Gabriel Fernandes; Marina De Brot; Márcio Moraes; Lucíola Barcelos; José Miguel Ortega; André Oliveira; M Fátima Leite Journal: PLoS One Date: 2017-04-04 Impact factor: 3.240